Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Moore, C. Rudman, N. MacLachlan, G. Fuller, B. Burnett, J. Frane (1988)
Equivalent potency and pharmacokinetics of recombinant human growth hormones with or without an N-terminal methionine.Endocrinology, 122 6
Yoko Tanaka, H. DeLuca (1973)
The control of 25-hydroxyvitamin D metabolism by inorganic phosphorus.Archives of biochemistry and biophysics, 154 2
D. Pahuja, H. DeLuca (1981)
Role of the hypophysis in the regulation of vitamin D metabolismMolecular and Cellular Endocrinology, 23
J. Caverzasio, J. Bonjour (1988)
Influence of recombinant IGF-I (somatomedin C) on sodium-dependent phosphate transport in cultured renal epithelium.Progress in clinical and biological research, 252
H. Tenenhouse, A. Klugerman, W. Gurd, M. Lapointe, G. Tannenbaum (1988)
Pituitary involvement in renal adaptation to phosphate deprivation.The American journal of physiology, 255 3 Pt 2
M. Hammerman, I. Karl, K. Hruska (1980)
Regulation of canine renal vesicle Pi transport by growth hormone and parathyroid hormone.Biochimica et biophysica acta, 603 2
T. Matsumoto, Y. Kawanobe, I. Ezawa, N. Shibuya, K. Hata, E. Ogata (1986)
Role of insulin in the increase in serum 1,25-dihydroxyvitamin D concentrations in response to phosphorus deprivation in streptozotocin-induced diabetic rats.Endocrinology, 118 4
J. Corvilain, M. Abramow (1964)
EFFECT OF GROWTH HORMONE ON TUBULAR TRANSPORT OF PHOSPHATE IN NORMAL AND PARATHYROIDECTOMIZED DOGS.The Journal of clinical investigation, 43
J. Caverzasio, J. Bonjour, H. Fleisch (1980)
Adaptation of tubular phosphate transport: relation between phosphate requirement, as influenced by growth, and supply.Advances in experimental medicine and biology, 128
T. Reinhardt, R. Horst, J. Orf, B. Hollis (1984)
A microassay for 1,25-dihydroxyvitamin D not requiring high performance liquid chromatography: application to clinical studies.The Journal of clinical endocrinology and metabolism, 58 1
K. Lyles, D. Halsey, N. Friedman, B. Lobaugh (1988)
Correlations of serum concentrations of 1,25-dihydroxyvitamin D, phosphorus, and parathyroid hormone in tumoral calcinosis.The Journal of clinical endocrinology and metabolism, 67 1
O. Fontaine, H. Pavlovitch, S. Balsan (1978)
25-Hydroxycholecalciferol metabolism in hypophysectomized rats.Endocrinology, 102 6
M. Lotz, E. Zisman, F. Bartter (1968)
Evidence for a phosphorus-depletion syndrome in man.The New England journal of medicine, 278 8
P. Henneman, A. Forbes, M. Moldawer, E. Dempsey, E. Carroll (1960)
Effects of human growth hormone in man.The Journal of clinical investigation, 39
R. Gray (1987)
Evidence that somatomedins mediate the effect of hypophosphatemia to increase serum 1,25-dihydroxyvitamin D3 levels in rats.Endocrinology, 121 2
J. Gertner, R. Horst, A. Broadus, H. Rasmussen, M. Genel (1979)
Parathyroid function and vitamin D metabolism during human growth hormone replacement.The Journal of clinical endocrinology and metabolism, 49 2
K. Ikeda, T. Matsumoto, K. Morita, Y. Kawanobe, I. Ezawa, E. Ogata (1987)
Role of insulin in the stimulation of renal 25-hydroxyvitamin D3-1 alpha-hydroxylase by phosphorus deprivation in rats.Metabolism: clinical and experimental, 36 6
A. Portale, B. Halloran, R. Morris (1989)
Physiologic regulation of the serum concentration of 1,25-dihydroxyvitamin D by phosphorus in normal men.The Journal of clinical investigation, 83 5
J. Chipman, J. Zerwekh, M. Nicar, J. Marks, C. Pak (1980)
Effect of Growth Hormone Administration: Reciprocal Changes in Serum lα,25-Dihydroxyvitamin D and Intestinal Calcium Absorption*The Journal of Clinical Endocrinology and Metabolism, 51
Stephen Burstein, I-Wen Chen, Reginald Tsang (1983)
Effects of growth hormone replacement therapy on 1,25-dihydroxyvitamin D and calcium metabolism.The Journal of clinical endocrinology and metabolism, 56 6
I. Maclntyre, K. Colston, M. Szelke, E. Spanos (1978)
A SURVEY OF THE HORMONAL FACTORS THAT CONTROL CALCIUM METABOLISM *Annals of the New York Academy of Sciences, 307
Animal studies have shown that GH is necessary for the increased renal production of calcitriol during dietary phosphorus deprivation (PD). These studies suggest that this adaptive change in vitamin D metabolism is mediated through insulin-like growth factor-I (IGF-I) and/or insulin. We subjected 16 GH-deficient children to 96 h of severe dietary PD twice, first before and again during recombinant GH replacement. Half of the children received low dose and half received high dose replacement with recombinant GH. We measured renal tubular reabsorption maximum for phosphate corrected for glomerular filtration rate (TmP/GFR), PTH, IGF-I, calcidiol, and calcitriol pre- and postdietary PD, both off and on GH. We also assessed insulin secretion during an oral glucose load (OGTT) off and on GH. Basal PTH, calcidiol, calcitriol, and fasting blood sugar were unaffected by GH therapy. PD did not affect PTH or calcidiol either off or on GH. Basal TmP/GFR rose on GH therapy (4.8 ± 0.2 to 6.3 ± 0.4 mg/dL) and with PD (4.8 ± 0.2 to 5.7 ± 0.2 mg/dL off and 6.3 ± 0.4 to 7.8 ± 0.3 mg/dL on GH). The increments due to PD and GH therapy were additive. The increments on GH were independent of the GH dose. Before GH replacement, calcitriol did not rise during PD (22.3 ± 2.1 to 23.3 ±1.9 pg/mL), but during GH therapy, PD caused a significant rise in calcitriol (23.8 ± 2.5 to 33.3 ± 2.4 pg/mL; P < 0.0001). The increment in calcitriol during PD was significantly greater in the high dose than it was in the low dose group (11.7 ± 1.5 vs. 7.2 ± 1.6 pg/mL; P < 0.05). GH therapy caused a rise in the IGF-I level that was significantly greater in the high dose (0.26 ± 0.03 to 3.15 ± 0.56 U/mL) than in the low dose (0.27 ± 0.02 to 0.68 ± 0.13 U/mL) group. Insulin in response to OGTT was significantly greater after GH therapy (4155 ± 600 μU/mL·min off GH; 6504 ± 1153 μU/mL·min on GH), although there was no difference between the low and high dose groups. Regression analysis demonstrated a correlation between the change in calcitriol during PD and the IGF-I level (r = 0.83). There was no correlation between insulin levels and the change in calcitriol or between IGF-I or insulin levels and the increment in TmP/GFR during GH therapy. We conclude that 1) GH exerts an effect on the kidney to cause phosphorus conservation, which may be a direct effect; 2) phosphorus conservation in response to PD is independent of GH in humans; 3) increased calcitriol generation in response to PD is dependent upon GH; 4) the increment in calcitriol during PD correlates significantly with IGF-I levels, but not with insulin, suggesting that it may be an IGF-I-mediated effect of GH. This content is only available as a PDF. Author notes * This work was supported by NIH Grant RR-6020 (to the Pediatric Clinical Research Center) and NCI Grant CA-29502 (to the Core Nutritional Research Unit). Copyright © 1990 by The Endocrine Society
Journal of Clinical Endocrinology and Metabolism – Oxford University Press
Published: Apr 1, 1990
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.